Clinical Trials
15 trialsNCT06987708 2026-06-15
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
Hackensack Meridian Health
Phase NA Not yet recruiting
NCT04776395 2026-06-01
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
Phase 2 Recruiting
NCT04731844 2026-05-12
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Phase 2 Completed
NCT02269592 2026-05-07
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
Recruiting
NCT01177527 2026-05-05
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
Active not recruiting
NCT07446777 2026-05-01
FAST-M
University of Miami
Phase NA Recruiting
NCT05014646 2026-04-30
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02726750 2026-04-21
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
M.D. Anderson Cancer Center
Recruiting
NCT05640843 2026-04-16
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT06383143 2026-04-16
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT02960555 2026-04-15
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05136807 2026-04-15
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
M.D. Anderson Cancer Center
Recruiting
NCT05361694 2026-04-09
TRANSFORMM
University of Miami
Recruiting
NCT07069751 2026-04-03
HiFi-MM
IRCCS San Raffaele
Phase NA Recruiting
NCT03236428 2026-03-27
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting